(Szuba et al., 2002) In follow-up studies, this group also showed that delivery of recombinant human VEGF-C improved outcomes in a mouse tail model of lymphedema by increasing lymphangiogenesis, improving the morphology of cutaneous lymphatic vessels, and the ability of lymphatic channels to transport immune cells. This evidence concerns the gene VEGFC and lymphedema.